DK0540588T3 - Preparation providing improved clearance of bioactive substances from the blood stream - Google Patents
Preparation providing improved clearance of bioactive substances from the blood streamInfo
- Publication number
- DK0540588T3 DK0540588T3 DK91913278.7T DK91913278T DK0540588T3 DK 0540588 T3 DK0540588 T3 DK 0540588T3 DK 91913278 T DK91913278 T DK 91913278T DK 0540588 T3 DK0540588 T3 DK 0540588T3
- Authority
- DK
- Denmark
- Prior art keywords
- bioactive substances
- blood stream
- providing improved
- improved clearance
- ligand
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 title abstract 3
- 239000000126 substance Substances 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 4
- 230000001413 cellular effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
A pharmaceutical or diagnostic composition comprises, in separate containers, (a) a capturing agent capable of binding to a bioactive substance as well as to a ligand or ligand analogue which is able to bind to a cellular receptor; and (b) a ligand or ligand analogue capable of binding to a cellular receptor as well as to said capturing agent. The composition may be used for providing the rapid clearance of bioactive substances from the circulation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK176290A DK176290D0 (en) | 1990-07-24 | 1990-07-24 | THERAPEUTIC AND DIAGNOSTIC PREPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0540588T3 true DK0540588T3 (en) | 1995-11-06 |
Family
ID=8107861
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK176290A DK176290D0 (en) | 1990-07-24 | 1990-07-24 | THERAPEUTIC AND DIAGNOSTIC PREPARATION |
DK91913278.7T DK0540588T3 (en) | 1990-07-24 | 1991-07-24 | Preparation providing improved clearance of bioactive substances from the blood stream |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK176290A DK176290D0 (en) | 1990-07-24 | 1990-07-24 | THERAPEUTIC AND DIAGNOSTIC PREPARATION |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0540588B1 (en) |
JP (1) | JPH05509092A (en) |
AT (1) | ATE123951T1 (en) |
AU (1) | AU659092B2 (en) |
CA (1) | CA2087971A1 (en) |
DE (1) | DE69110679T2 (en) |
DK (2) | DK176290D0 (en) |
FI (1) | FI930269A (en) |
GR (1) | GR3017362T3 (en) |
NO (1) | NO930218L (en) |
WO (1) | WO1992001469A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
GB9705521D0 (en) * | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
KR100452125B1 (en) * | 2002-07-30 | 2004-10-12 | 주식회사 바이오알앤즈 | Novel Bacillus subtilis BRD-007 strain having food waste decompositing capability and microbial agent for food waste treatment using it |
IL182956A0 (en) * | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3484198D1 (en) * | 1983-07-29 | 1991-04-04 | Milton David Goldenberg | METHOD FOR INCREASING TARGET SPECIFICITY IN ANTIBODY DETERMINATIONS AND FOR CLEARING NON-TARGET SPECIFIC DIAGNOSTIC AND THERAPEUTIC FACTORS. |
US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
AU595173B2 (en) * | 1985-01-08 | 1990-03-29 | General Hospital Corporation, The | Method and use for site-specific activation of substances |
US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
US4932412A (en) * | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
GB8728856D0 (en) * | 1987-12-10 | 1988-01-27 | Bradwell A R | Tumour-locating agents & method of locating tumours |
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
-
1990
- 1990-07-24 DK DK176290A patent/DK176290D0/en not_active Application Discontinuation
-
1991
- 1991-07-24 DK DK91913278.7T patent/DK0540588T3/en active
- 1991-07-24 AU AU82828/91A patent/AU659092B2/en not_active Ceased
- 1991-07-24 AT AT91913278T patent/ATE123951T1/en not_active IP Right Cessation
- 1991-07-24 WO PCT/DK1991/000215 patent/WO1992001469A1/en active IP Right Grant
- 1991-07-24 EP EP91913278A patent/EP0540588B1/en not_active Expired - Lifetime
- 1991-07-24 DE DE69110679T patent/DE69110679T2/en not_active Expired - Fee Related
- 1991-07-24 JP JP3512515A patent/JPH05509092A/en active Pending
- 1991-07-24 CA CA002087971A patent/CA2087971A1/en not_active Abandoned
-
1993
- 1993-01-22 FI FI930269A patent/FI930269A/en not_active Application Discontinuation
- 1993-01-22 NO NO93930218A patent/NO930218L/en unknown
-
1995
- 1995-09-13 GR GR950402478T patent/GR3017362T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE123951T1 (en) | 1995-07-15 |
NO930218L (en) | 1993-03-24 |
GR3017362T3 (en) | 1995-12-31 |
DE69110679D1 (en) | 1995-07-27 |
FI930269A0 (en) | 1993-01-22 |
EP0540588B1 (en) | 1995-06-21 |
EP0540588A1 (en) | 1993-05-12 |
AU659092B2 (en) | 1995-05-11 |
DE69110679T2 (en) | 1995-11-09 |
AU8282891A (en) | 1992-02-18 |
WO1992001469A1 (en) | 1992-02-06 |
NO930218D0 (en) | 1993-01-22 |
CA2087971A1 (en) | 1992-01-25 |
FI930269A (en) | 1993-03-22 |
JPH05509092A (en) | 1993-12-16 |
DK176290D0 (en) | 1990-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9203370A (en) | DESULFATOHIRUDINA AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT. | |
DE69230670D1 (en) | COMPOSITIONS CONTAINING A BLOOD CLOTH POLYMER MATRIX FOR THE ADMINISTRATION OF OSTEOGENIC PROTEINS | |
ATE2271T1 (en) | 4-(SUBSTITUTED THIAZOLYL)-3-HYDROXY-3-PYRROLINE2,5-DIONE COMPOUNDS, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
ATE83374T1 (en) | NEW GALENIC FORM OF FENOFIBRATE. | |
ATE7697T1 (en) | SUBSTITUTED PYRAZINYL-1,2,4-OXADIAZOLE-5-ONE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
DK0497240T3 (en) | Composition for controlled release of active substances for ruminants | |
MX9102353A (en) | N, O-SULPHATES OF HEPAROSANES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINED IN THEM. | |
BR9711098B1 (en) | heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases. | |
ATE26705T1 (en) | 1-CARBOXYALKANOYLINDOLINE-2-CARBONIC ACIDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS. | |
MX9305146A (en) | CONJUGATE OF INTERFERON, PROCEDURE FOR ITS PRERATION AND PHARMACEUTICAL COMPOSITION THAT CONTAIN IT. | |
DK0399902T3 (en) | Porous pharmaceutical formulation and preparation thereof | |
MX9102500A (en) | BIPHENYLIUM COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
DE59813229D1 (en) | STABLE EXTRACT OF HYPERICUM PERFORATUM L., PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL PREPARATIONS | |
BR9306345A (en) | Methods to suppress the ability of a mammal's t-cells to proliferate and to suppress immune response compositions for use in suppressing the ability of t-cells to proliferate and in suppressing the immune response | |
ATE222897T1 (en) | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
MX24890A (en) | SYNTHETIC POLYPEPTIDE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT. | |
DK0540588T3 (en) | Preparation providing improved clearance of bioactive substances from the blood stream | |
DE3887068D1 (en) | 2,2-Dimethylchromene derivatives, process for their preparation and pharmaceutical compositions containing them. | |
ATE8880T1 (en) | NEW CARBAMATS, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. | |
ES488301A0 (en) | PROCEDURE FOR OBTAINING DEHYDROPEPTIDES | |
DE3850044D1 (en) | Azelastine embonate, process for its preparation and pharmaceutical preparations containing azelastine embonate as active ingredient. | |
DE3879837D1 (en) | PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CERBERAL PSYCHO-ORGANIC SYNDROME. | |
ATE111461T1 (en) | N-((2-THENOYLMERKAPTO-3-METHYL)-BUTANOYL>- HOMOCYSTEIN THIOLACTONE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
ATE49956T1 (en) | N,N-BIS-(4FLUOROPHENYL)CARBAMOYLACETOHYDROXAMS|URE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
ATE22288T1 (en) | PYRIMIDINE COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |